# José Antonio Mesa

> José Antonio Mesa is a Series A investor at Alta Life Sciences backing Biotechnology. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Alta Life Sciences](https://shizune.co/investors/profile/alta-life-sciences)
- Location: Barcelona, Spain
- Total investments: 7
- Last investment: Jun 2026
- Lead investor: 57%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/in/joseantoniomesa
- X (Twitter): http://twitter.com/eplorans

José Antonio Mesa is a Series A investor at Alta Life Sciences in Barcelona focused on Biotechnology and Life Science. Mr. José Antonio Mesa is an Investment Director at Caixa Capital Risc, SGECR, S.A.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 57% |
| Life Science | 2 | 29% |
| Genetics | 1 | 14% |
| Health Care | 1 | 14% |
| Therapeutics | 1 | 14% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 29% |
| Series B | 2 | 29% |
| Venture - Series Unknown | 2 | 29% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Ona Therapeutics | Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine. | $86.6M | Series B | Jun 04, 2026 |  |
| Ona Therapeutics | Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine. | $11.6M | Venture - Series Unknown | Oct 09, 2025 |  |
| ARTHEx Biotech | ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successfuldevelopment of our products. | $40.6M | Series B | Sep 17, 2025 |  |
| ARTHEx Biotech | ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successfuldevelopment of our products. | $46.5M | Series B | May 03, 2023 |  |
| Inbiomotion | Inbiomotion is focused on the development and commercialization of a biomarker that predicts metastasis to improve patients' quality of life by personalizing the adjuvant treatment of early stage breast cancer. Founded in 2010 by Dr. Roger Gomis, it is a spin-off of IRB Barcelona and ICREA research institutions.Inbiomotion's uniquediagnostic assay is based on a highly selective single gene biomarker. Data generated thus far suggests such biomarker can identify early stage breast cancer patients that will benefit from bisphosphonate adjuvant treatment improving their overall and invasive disease free survival. It can further predict at an early stage a patient's risk of metastases relapse from primary tumors. The selectivity of the lead biomarker has the potential to advance the clinical standard of care using personalized medicine. |  | Venture - Series Unknown | Jan 21, 2021 |  |
| DeepUll | DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functionalstatus on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise. | $3.9M | Series A | Jul 07, 2020 |  |
| Ona Therapeutics | Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine. | $33.8M | Series A | Jun 16, 2020 |  |

7 of 7 investments shown.

## Co-investors
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 4 deals together
- [Fund+](https://shizune.co/investors/profile/fund) — VC Fund, 4 deals together
- [Invivo Capital Partners](https://shizune.co/investors/profile/invivo-capital-partners) — VC Fund, 4 deals together
- [Asabys Partners](https://shizune.co/investors/profile/asabys-partners) — VC Fund, 3 deals together
- [CDTI Innovación's INNVIERTE program](https://shizune.co/investors/profile/cdti-innovaci%C3%B3n-s-innvierte-program) — VC Fund, 3 deals together
- [Ysios Capital](https://shizune.co/investors/profile/ysios-capital) — VC Fund, 3 deals together

## About Alta Life Sciences

VC Fund · Barcelona, Spain

Alta Life Sciences is a leading multistage venture capital investment firm. Alta LS will invest in companies at all stages of development: from seed financing through commercial growth. Alta LS invests in all areas of life sciences including biotechnology, medical devices, diagnostics, genomics and digital health.

5 contacts available at Alta Life Sciences.

| Name | Title | Profile |
| --- | --- | --- |
| Guy P. Nohra | Managing General Partner | https://shizune.co/investors/profile/guy-p-nohra |
| Scott Moonly | General Partner | https://shizune.co/investors/profile/scott-moonly |
| José Antonio Mesa | Partner | https://shizune.co/investors/profile/jos-antonio-mesa |
| Miguel Valls | General Partner | https://shizune.co/investors/profile/miguel-valls |
| Montserrat Vendrell | Partner | https://shizune.co/investors/profile/montserrat-vendrell |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does José Antonio Mesa invest in?

José Antonio Mesa invests primarily in Biotechnology, Life Science and Genetics startups, most often at Series A and Series B stage. Most of the 7 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did José Antonio Mesa last invest?

The most recent investment recorded for José Antonio Mesa closed in Jun 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co